Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of Hull
- Target Recruit Count
- 60
- Registration Number
- NCT05646199
- Locations
- 🇬🇧
Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
A Study of Effect of LY3556050 on Metformin in Healthy Participants
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT05615467
- Locations
- 🇺🇸
PRA International, Salt Lake City, Utah, United States
A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT05615012
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
Evaluating the Efficacy and Safety of Metformin in Vitiligo
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 30
- Registration Number
- NCT05607316
- Locations
- 🇺🇸
UMass Chan Medical School, Worcester, Massachusetts, United States
Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2022-10-24
- Target Recruit Count
- 60
- Registration Number
- NCT05591235
Metformin Treatment in Infants After Perinatal Brain Injury
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 1
- Registration Number
- NCT05590676
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontartio, Canada
A Study of LY3526318 in Healthy Male Japanese Participants
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT05580250
- Locations
- 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan
Clinical Trial of Crocus Kozanis Administration in Obese Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 75
- Registration Number
- NCT05572749
- Locations
- 🇬🇷
Unit of Paediatric Endocrinology and Metabolism, 2nd Department of Paediatrics, AHEPA University Hospital, Thessaloniki, Greece
Metformin as Added on Therapy in Patients With Ulcerative Colitis
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 46
- Registration Number
- NCT05574387
- Locations
- 🇪🇬
Faculty of Medicine, Mansoura University, Mansoura, Egypt
Effect of Metformin Use on Mortality in Diabetic and Non Diabetic Patients With Sepsis and Septic Shock.
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 75
- Registration Number
- NCT05572060
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.